underappreci lower
pt due spin
believ merck made right busi decis spin
legaci asset rais total merck ep est extend
model new total ep consensu
reiter ow rate lower pt
due lower multipl newco ep
order get bigger merck first need get smaller believ merck exit
legaci product right busi decis enabl
effici focus merck drive greater valu creation long term
merck priorit higher valu faster growth franchis merck exit
estim oper incom revenue midpoint oper
margin newco stand-up cost expect save three
year loss oper incom ultim
understand newco margin follow oper
margin pre-exit percentag point stand-up cost yield add
bp yield ebitda importantli merck concentr
busi oper capit higher-valu franchis compani
focu attent enhanc optim portfolio long-term
project total merck result increasingli consensu next
sever year rais total merck ep extend
model ep consensu
think street
significantli under-appreci benefit merck doubl
gardasil manufactur capac open two new bulk facil
gross margin expans oper leverag benefit come year
keytruda royalti payment step januari royalti bmy/ono
decreas basi point project revenu
consensu ep consensu yet built full
remainco model exit newco could bump long-term
compound-annual-growth-rate ep consensu current model merck
ep compound-annual-growth-rate new vs old ms vs consensu estim
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
keytruda concentr issu regard plan spin
newco bear emphas greater keytruda concentr fail
consid greater concentr high-valu durabl vaccin anim health
franchis regard fundament consider view
follow assum keytruda succeed adjuv trial
fail come year although keytryda face competit threat
assum keytruda efficaci bar remain difficult beat novel
therapi outperform keytruda day regimen would like carri
addit toxic would like rais question benefit-risk ratio
rel keytruda regard risk keytruda biosimilar
expect merck develop intern pipelin execut blunt
risk time
think remainco price-to-earnings multipl trade ep yield
remainco stock price discuss posit neg consider
rais total merck assum
dilut spin yield remainco ep note management
estim dilut rang assum cost save
cash proce use repurchas share remainco target multipl
prior target price-to-earnings total repres estimate long-term
ep growth current total merck consid
balanc posit neg factor remainco stock multipl posit
higher lt ep growth could rise greater
concentr highli durabl high multipl revenu stream remov
newco revenu drive vaccin total anim
total optim portfolio corpor focu
growth remainco stock multipl neg greater concentr keytruda
rise transact draw investor debat
regard right multipl assign
lower total merck pt old pt prior
ep calcul new pt two compon
remainco ep plu estimate valu spin-off assign
price-to-earnings believ optim merck faster growth prospect
balanc slightli greater keytruda concentr estim newco spin-
valu follow project adj ebitda assum
ebitda margin rev multipli potenti multipl
subtract new debt cash paid merck yield potenti equiti valu
divid share outstand valu
sharehold spin note newco could trade higher ebitda
multipl investor develop convict growth prospect manag
expect newco grow revenu low singl digit drive margin
expans om level
act financi advisor merck co merck connect
intent spin-off product women legaci brand
biosimilar franchis new yet-to-be-nam independ publicly-trad
compani announc februari transact subject market
certain condit merck agre pay fee
financi servic includ fee conting upon consumm
transact pleas refer note end report
base case remainco ep base case newco ebitda remainco
target multipl slight premium target peer averag believ
justi given faster growth prospect balanc slightli greater keytruda concentr
newco target multipl reect modest growth potenti note estimate debt newco
need subtract ev calcul potenti market cap
overweight merck base upon
compel long-term growth prospect
stream optim portfolio
see upsid lt consensu driven
total merck remainco newco
pipelin option diseas beyond
oncolog come focu come
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
merck deliv sale margin expans
merck deliv sale margin expans
earli merck execut compel
earli merck execut compel
ep forecast due higher-than-
valu higher anticip
merck deliv sale ep
merck deliv sale ep
expect drive upsid out-year
expect drive upsid out-year
consensu key driver keytruda
gardasil expect margin
expand consensu project
keytruda adjuv trialssucce
less inspir keytruda
keytruda gardasil disappoint
keytruda gardasil disappoint
drive ep forecast
drive ep forecast keytruda fail
ratio rel keytruda pipelin shortfal
market valu newco lower
keytruda chemo phase readout tnbc vs chemo
readout pzer prevnar -- efcaci
implic percept
immuno-oncolog trial result
keytruda sale trend trial develop
immuno-oncolog news ow competitor
china india
view explan region hierarchi
research highest favor quintil
upsid risk posit nancial surpris earli
competitor shortfal value-enhanc
downsid risk nancial shortfal key
 regulatori risk lower expect stock
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
new vs old ms vs consensu estim
exhibit incom statement margin valuat
sg sale
 sale
exhibit balanc sheet statement
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
